Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis → Estee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI company (From Financial Markets Daily) (Ad) Free DXCM Stock Alerts $114.26 -2.94 (-2.51%) (As of 12:57 PM ET) Add Compare Share Share Today's Range$113.77▼$116.3350-Day Range$115.23▼$140.4552-Week Range$74.75▼$142.00Volume732,983 shsAverage Volume2.90 million shsMarket Capitalization$45.44 billionP/E Ratio73.72Dividend YieldN/APrice Target$140.94 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside23.3% Upside$140.94 Price TargetShort InterestHealthy2.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.84Based on 18 Articles This WeekInsider TradingSelling Shares$8.38 M Sold Last QuarterProj. Earnings Growth25.28%From $1.78 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector29th out of 913 stocksSurgical & Medical Instruments Industry6th out of 100 stocks 3.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.20% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 12.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 2.1 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for DexCom this week, compared to 13 articles on an average week.Search InterestOnly 15 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,377,125.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 25.28% in the coming year, from $1.78 to $2.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 73.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.49.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 73.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.92.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.85. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 21.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Financial Markets DailyEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Discover this unknown NYSE Tech SaaS company About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesJune 12 at 6:49 AM | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $49,126.35 in StockJune 3, 2024 | insidertrades.comMichael Jon Brown Sells 652 Shares of DexCom, Inc. (NASDAQ:DXCM) StockJune 13 at 8:09 AM | americanbankingnews.comSadie Stern Sells 427 Shares of DexCom, Inc. (NASDAQ:DXCM) StockJune 13 at 6:42 AM | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) CFO Sells $85,712.25 in StockJune 11 at 2:54 AM | americanbankingnews.comDexCom (NASDAQ:DXCM) Downgraded by StockNews.com to "Hold"June 5, 2024 | businesswire.comDexcom G7 Now Connects Directly to Apple Watch in the U.S.June 4, 2024 | businesswire.comDexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 DiabetesJune 3, 2024 | fool.comBull Market Buys: 2 Growth Stocks to Own for the Long HaulJune 3, 2024 | americanbankingnews.comDexCom (NASDAQ:DXCM) Upgraded to "Buy" at StockNews.comMay 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024May 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024May 29, 2024 | businesswire.comDexcom Announces Upcoming Conference PresentationMay 29, 2024 | businesswire.comTandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGMMay 27, 2024 | investorplace.com3 Growth Stocks the New ‘GPT-4o' AI Bot Says Will Make You RichMay 26, 2024 | finance.yahoo.comWith EPS Growth And More, DexCom (NASDAQ:DXCM) Makes An Interesting CaseMay 24, 2024 | markets.businessinsider.comDexcom’s Continued Market Leadership Amid Limited Competition from Roche’s CGMMay 20, 2024 | businesswire.comDexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 DiabetesMay 18, 2024 | ca.finance.yahoo.comDXCM May 2024 133.000 putMay 17, 2024 | forbes.comWill DexCom Offer Better Returns Than 3M Stock?May 16, 2024 | finance.yahoo.comInsider Sale: EVP Strategy and Corporate Development Matthew Dolan Sells Shares of DexCom Inc (DXCM)May 14, 2024 | finance.yahoo.comFrank Sands' Strategic Moves in Q1 2024: A Closer Look at DexCom Inc's Portfolio ImpactMay 13, 2024 | seekingalpha.comDexcom: Positive Catalysts Ahead To Support GrowthMay 13, 2024 | fool.comBull Market and Beyond: 2 Stocks Just Waiting to SoarMay 12, 2024 | finance.yahoo.comInvestors Will Want DexCom's (NASDAQ:DXCM) Growth In ROCE To PersistMay 8, 2024 | finance.yahoo.comEstimating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)See More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today6/13/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$140.94 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside+20.3%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio75.61 Forward P/E Ratio65.84 P/E Growth2.85Net Income$541.50 million Net Margins16.82% Pretax Margin20.48% Return on Equity31.01% Return on Assets10.29% Debt Debt-to-Equity Ratio1.08 Current Ratio2.90 Quick Ratio2.53 Sales & Book Value Annual Sales$3.62 billion Price / Sales12.87 Cash Flow$2.08 per share Price / Cash Flow56.33 Book Value$5.35 per share Price / Book21.91Miscellaneous Outstanding Shares397,680,000Free Float396,491,000Market Cap$46.61 billion OptionableOptionable Beta1.22 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $3.23MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $1.13MMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $1.29MMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $1.22MMs. Teri Lawver (Age 57)Executive VP & Chief Commercial Officer Comp: $1.41MMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMore ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCRIntuitive SurgicalNASDAQ:ISRGStrykerNYSE:SYKBoston ScientificNYSE:BSXView All CompetitorsInsiders & InstitutionsAmerican TrustBought 1,528 shares on 6/11/2024Ownership: 0.000%Jereme M SylvainSold 745 sharesTotal: $85,712.25 ($115.05/share)Sadie SternSold 427 sharesTotal: $49,126.35 ($115.05/share)DekaBank Deutsche GirozentraleSold 218,494 shares on 6/4/2024Ownership: 0.211%Michael Jon BrownSold 652 sharesTotal: $77,744.48 ($119.24/share)View All Insider TransactionsView All Institutional Transactions Should I Buy DexCom Stock? DXCM Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom's recent strong quarterly earnings report, beating analysts' estimates, indicates a positive financial performance. The company's focus on continuous glucose monitoring (CGM) systems for diabetes management aligns with the growing demand for healthcare technology. Positive analyst ratings and price target upgrades suggest confidence in DexCom's future growth potential. Insider selling activities may not necessarily indicate negative sentiment, as executives may sell for various personal financial planning reasons. Despite recent fluctuations, DexCom's stock price has shown resilience and maintained an upward trend, reflecting investor confidence. Cons Investors should be bearish about investing in DexCom, Inc. for these reasons: High price-to-earnings ratio and price-to-earnings-growth ratio may indicate an overvalued stock, potentially leading to limited upside for investors. Market volatility and competition in the healthcare technology sector could pose challenges to DexCom's market share and profitability. Executive insider selling activities, although common, could raise concerns about the company's future performance or growth prospects. Dependency on regulatory approvals and healthcare industry regulations may impact DexCom's product development timelines and market access. Investors should carefully consider the company's debt-to-equity ratio and financial leverage when evaluating investment risks. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 31, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com. DXCM Stock Analysis - Frequently Asked Questions Should I buy or sell DexCom stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price target for 2024? 15 Wall Street analysts have issued twelve-month target prices for DexCom's shares. Their DXCM share price targets range from $100.00 to $165.00. On average, they predict the company's stock price to reach $140.94 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2024? DexCom's stock was trading at $124.09 at the beginning of the year. Since then, DXCM stock has decreased by 7.9% and is now trading at $114.26. View the best growth stocks for 2024 here. Are investors shorting DexCom? DexCom saw a increase in short interest in May. As of May 31st, there was short interest totaling 8,740,000 shares, an increase of 12.3% from the May 15th total of 7,780,000 shares. Based on an average daily trading volume, of 2,690,000 shares, the days-to-cover ratio is presently 3.2 days. View DexCom's Short Interest. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our DXCM earnings forecast. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, April, 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The medical device company earned $921 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a trailing twelve-month return on equity of 31.01%. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), Harbor Health Care ETF (MEDI), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Natixis Vaughan Nelson Select ETF (VNSE) and American Century Mid Cap Growth Impact (MID). When did DexCom's stock split? DexCom's stock split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom updated its FY 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). Who are DexCom's major shareholders? DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.22%), Baillie Gifford & Co. (3.94%), Capital Research Global Investors (3.38%), Capital World Investors (2.03%), Blair William & Co. IL (1.14%) and Price T Rowe Associates Inc. MD (0.74%). Insiders that own company stock include Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More This page (NASDAQ:DXCM) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerf...Stansberry Research | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
